摘要
Abstract
Objective To investigate the clinical efficacy of tirofiban in the treatment of acute non-ST-segment elevation myocardial infarction (NSTEMI). Methods 140 cases of patients with acute non-ST-segment elevation myocardial infarction treated in our hospital from September 2011 to April 2014 were selected as research objects, all patients were divided into observation group and control group according to random number table, with 70 cases in each group. The control group was treated with conventional therapy, while the observation group was given tirofiban on the basis of routine treatment. The clinical effect of two groups were compared. Results The platelet count of two groups before and after treatment had no significant difference (P>0.05);but the platelet aggregation, cTNI level and CK-MB level after treatment of two groups were significantly improved, and the improvement degree of observation group was better than that of control group, the difference was statistical (P<0.01). The total effective rate of observation group was 91.43%, significantly higher than 71.43%of control group, with statistical difference (P<0.01);the incidence of major adverse cardiac events (MACE) in observation group was 11.43%, lower than 31.43%in control group, with statistical difference (P<0.01). Conclusions Tirofiban has remarkable effect in the treatment of acute non-ST-segment elevation myocardial infarction, and can effectively reduce the incidence of major cardiovascular events and HS-CRP, which is safe and effective, and deserves clinical application.关键词
替罗非班/急性非ST段抬高性心肌梗死Key words
Tirofiban/Acute non-ST-segment elevation myocardial infarction分类
医药卫生
